This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
5 Top Stocks Up 100%+ in May With More Room to Run
by Tirthankar Chakraborty
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
Is CymaBay Therapeutics (CBAY) Stock a Solid Choice Right Now?
by Zacks Equity Research
CymaBay Therapeutics (CBAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Do Options Traders Know Something About CymaBay Therapeutics (CBAY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.
Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
by Zacks Equity Research
Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.
Is the Options Market Predicting a Spike in CymaBay Therapeutics (CBAY) Stock?
by Zacks Equity Research
Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.
CymaBay Therapeutics Enters Oversold Territory
by Zacks Equity Research
CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Gilead (GILD) Announces Top-Line Results From NASH Study
by Zacks Equity Research
Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
NASH Scorecard Year to Date: The Winners and the Losers
by Ekta Bagri
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates.
Company News For Nov 26, 2019
by Zacks Equity Research
Companies In The News Are:
Intercept's (ICPT) NDA for NASH Drug Gets Priority Review
by Zacks Equity Research
Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
by Zacks Equity Research
CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock
by Zacks Equity Research
CymaBay Therapeutics (CBAY) needs investors to pay close attention to the stock based on moves in the options market lately.
New Strong Sell Stocks for August 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for July 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for July 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher
by Zacks Equity Research
CymaBay Therapeutics (CBAY) was a big mover last session, as the company saw its shares rise more than 11% on the day.
Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season
by Zacks Equity Research
CymaBay Therapeutics (CBAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2%
by Zacks Equity Research
Cymabay Therapeutics, Inc. (CBAY) moved big last session, as its shares rose over 6% on the day.
Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cymabay Therapeutics (CBAY) stock based on the movements in the options market lately.
New Analyst Coverage Make These 5 Stocks Worth a Bet
by Zacks Equity Research
Most investors depend on analysts' research before taking decisions as they fear that lack of information might trigger inefficiencies. Here, analysts play a vital intermediary role with their extensive access to relevant data.
Will Cymabay Therapeutics (CBAY) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cymabay Therapeutics, Inc. (CBAY)